50 A cross-sectional study of 43 women cared for in an outpatient urology center found that the annual direct cost associated with a diagnosis of IC/BPS based on Medicare rates was $3,631 per person, while the estimated costs based on non-Medicare rates was nearly twice that amount
Gutierrez M
Furthermore, Joo et al
Moreover, the recent dual GIP/GLP-1 receptor agonist tirzepatide promoted greater decrease of liver fat content and of the volume of visceral adipose tissue vs
Record symptoms along with their timing, severity, and relationship to doses, meals, and hydration status
Reducing the most harmful drinking patterns could make a meaningful difference for patients. In a linked commentary, also published in The Lancet, academics from the US said: The importance of evaluating GLP-1 therapies as new therapeutic options for alcohol use disorder cannot be overstated, Should forthcoming studies confirm efficacy of GLP-1 therapies for alcohol use disorder across a broad range of populations and settings, public health implications could be substantial a possibility that deserves celebration. Commenting on the study, Dr Marie Spreckley, research programme manager at the University of Cambridge, said: Overall, this study provides encouraging early evidence for a potential new treatment approach for people with co-occurring obesity and alcohol use disorder, but larger and longer-term trials in more diverse populations are needed before this can inform routine clinical practice. Matt Field, professor of psychology at the University of Sheffield, said: This well-conducted trial showed that 26 weeks of semaglutide treatment led to a marked reduction in the frequency of heavy drinking among people with alcohol use disorder who were also obese
